ElevateBio LLC, a cell and gene therapy technology company that focuses on powering transformative cell and gene therapies has acquired the entirety of AgBiome Delta, LLC’s Life Edit Therapeutics, Inc.
Life Edit brings a suite of gene editing technologies along with a divers array of RNA-guided nucleases and base editors that offer broad genome access. The purchase brings a portfolio of editing modalities, deletion, insertion, base editing and CRISPRa/CRISPRi.
“Genome editing is a central component of all cell and gene therapy development, and access to novel RNA-guided nucleases and base editors that offer specificity and broad genome coverage will be critical,” said Mitchel Finer, CEO of Life Edit and president of R&D at ElevateBio. “We believe Life Edit’s technology is one of the most versatile in the field, opening up enormous potential.”